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MENOPAUSE IN CENTRAL AMERICA: ATTITUDES, SYMPTOMS AND
TREATMENT
G. Mahady1, A. Perez2, A. Caceres3, T. Locklear1, B. Doyle4, J. Michel5.
1University of Illinois at Chicago, Pharmacy Practice, Chicago, United States;
2University of Costa Rica, CIPRONA, San Jose, Costa Rica; 3University of San
Carlos, Guatemala City, Guatemala; 4University of Illinois at Chicago,
Medicine, Chicago, United States; 5University of Illinois at Chicago, Public
Health, Chicago, United States
Objectives: To investigate the attitudes and symptoms associated with the
menopausal transition in Guatemalan and Costa Rican women and the
therapies used to treat these symptoms.
Methods: As part of an NIH funded project, interviews of women, mid-
wives, healers and medical personnel were performed. Plants used to treat
menopause were collected in Guatemala and Costa Rica, extracted and
tested.
Results: Women living in Central America have a more positive attitude
toward menopause that their U.S. counterparts. While women in Guatemala
have slightly fewer symptoms, women in Costa Rica have menopausal
symptoms similar to that observed in U.S. women. However, neither
women from Guatemala nor Costa Rica use HRT extensively and use herbal
products instead to treat the symptoms associated with menopause. Plant
species used as symptomatic treatment were collected and tested for
potential biological activities. Many of the herbal remedies were active
in multiple bioassays, suggesting a pleotropic and plausible mechanism
of action for the treatment of anxiety, depression, vasomotor symptoms
associated with the menopausal transition.
Conclusions: Women in Central American countries have similar symptoms
during menopause as their U.S, counterparts but have a more positive
outlook on the transition, as it marks an end to the reproductive years
and allows for more sexual freedom. These women however, do not use
HRT to any great extent, but opt for more natural therapies such as herbal
medicines and massage. Many of the herbal products used appear to have
a plausible mechanism of action.
Keywords: Menopause, Guatemala, Costa Rica, herbal, symptoms, vasomo-
tor.
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FREQUENCY AND TREATMENT OF MENORRHAGIA
A. Daneva-Markova. University Clinic of Obsterics and Gynecology, Clinic of
Obsterics and Gynecology, Skopje, Macedonia, the Former Yugoslav Republic of
Objectives: Our aim was to ﬁnd the best way in treating women who
suffer from prologed and heavy menstrual bleeding in various age groups.
Methods: We retrospectively analysed patients who had that problem in
period of two years, we compared two groups by different causes: ovarian
dysfunction on one side and some organic disease (myoma, polypus, in-
ﬂammation). We also compared frequency in different age and coincidence
with postoperative treatment with Th. Tamoxifen, and their treatment.
Results: There were 140 women with abnormal bleeding from uerus, 55 of
them had menorrhagia (39%). Among them 16 (31%) were between 18-45
years old, 35 (61%) between 45-50, and 9 (8%) over 50 years. Organic
cause- 28 (46%) patients, 5 (20%) polypus cervicalis, 10 (25%) polypus
endometrialis, 12 (38%) myoma uteri and 3 (14%) inﬂammation. The rest
of them, 30 patients had ovarian dysfunction and most of them belong to
group between 45-50 years, 52 patients had a heavy bleeding and we did
curettage explorative, in 11 we found association with postoperative treat-
ment with Th. Tamoxifen.And 16 patients were treated with medicament 9
gestagens, ergometrin. Connected with cause of bleeding as well s with the
age we used different Therapy. 9 oral contraceptives, 10 with gestagenes,
8 operated, IUD with gestagen to 17 women. We had to do Re curettage
explorative in 7 patients.
Conclusions: 45-50 years of age is the period of menopause. We recom-
mended theapy IUD with gestagene as more convenient for women.
Keywords: Menorrhagia, IUD, treatment.
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VALUATION FULFILLMENT OF PATIENTS DEALT WITH RALOXIFENO AND
EFFECTS OF THE THERAPY ON THE ENDOMETRIUM
M. Sosa Marrero1, L. Estevez Suárez2, L. Galvan Montesdeoca2, C. Delgado
Godoy2, R. Hurtado Rodriguez2. 1Maternal-nfantil University Hospital of
Canarias-Las Palmas, Gynecology, Telde, Spain; 2Maternal-nfantil University
Hospital of Canarias-Las Palmas, Gynecology, Las Palmas, Spain
Objectives: analyze the fulﬁllment of the indicated medication the rate of
abandonment and its causes and to determine if the raloxifeno exerts a
proliferativa action on the endometrium
Methods: 103 postmenopausicas of 600 interviewed people included
themselves in the study, without THS or with a period superior to 6
months without this treatment. The basal visit took place, treatment was
indicated with Raloxifenoand Calciovit.Dbeing patient asintomáticas with
high osteoporótico risk according to clinical scale.
Results: Of all the patients including we only could ﬁnish the study in 72
(69.9%) with 31 patients to whom it was not possible to be included, of
these 22 by abandonment of the treatment by diverse causes emphasizing
that 14 did it by not specialized facultative indication and 9 did not go
to some of the controls. Them pautó tto with raloxifeno and was come to
controls similar to the 6 and 12 months.
The analysis of the collected data sample that do not exist signiﬁcant
differences in the thickness of the line endometrial of the women including
in this one study, during the ﬁrst 6 and 12 months. There was no case
of bled genital Conclusions: We can conclude that the high rate of a by
medical indication locates to us in the ignorance that continues existing
in primary attention of the therapies of the climacteric-menopause and
that during this period of time, the therapy with raloxifeno does not cause
substantial changes of the endometrium.
Keywords: Endometyum FULFILLMENT raloxifeno
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POSTOPERATIVE TACTICS FOR TREATING PATIENTS WITH CLIMACTERIC
SYNDROME AND CONNECTIVE TISSUE DYSPLASIA
K. Mylytsya, N. Lutsenko. Medical Academy of Postgraduate Education,
Zaporizhzhya, Ukraine
Objectives: The aim of the research is to study the predisposing factors
of hernia development with patients with climacteric syndrome and non-
differentiated connective tissue dysplasia and to deﬁne the postoperative
treatment tactics.
Methods: Surveying and antropometrying 400 surgery clinic patients for
the occurance of connective tissue dysplasia (CTD). The phenotypical
symptoms have been found with 118 patients, including 42 males and
76 females. 49 female patients with CTD have been diagnosed having
climacteric syndrome (CS).
Results: The results of the experimental and clinical - morphologyc
research prove the imbalance of collagen formation as well as inhibited
aponeurosis cicatrical tissue formation (up to 12 months), followed by its
failure during the postoperative treatment in case of CTD. When CTD is
accompanied by CS with the characteristic reduction of collagen formation,
it leads to inter-hindering inﬂuence, which results in hernia development,
including the post-operative ones, as well as abdominal circumference
increase and formation of pendulous abdomen.
Conclusions: In case of surgical treatment of female patients with CS and
CTD to prevent post-operatibe hernia formation and pendulous abdomen,
it’s necessary to use grid transplant and during the post-operative period
it’s necessary to give hormones replacement therapy during at least 12
months (unless there are some contraindications).
Keywords: Climacteric syndrome, connective tissue dysplasia, hernia,
hormone replacement therapy.
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P53 EXPRESSION IS DOWN-REGULATED IN LICHEN SCLEROSUS DURING
PIMECROLIMUS (ELIDEL®) TREATMENT
R. Nissi. Kemi Central Hospital, Kemi, Finland
Objectives: Pimecrolimus cream 1% (Elidel®) has recently been successfully
indicated for inﬂammatory cutaneus diseases. However, there are no
